grade
pharmaceutical primary standard
manufacturer/tradename
USP
mp
227-229 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
CCN1C=C(C(O)=O)C(=O)c2ccc(C)nc12
InChI
1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)
InChI key
MHWLWQUZZRMNGJ-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Still not finding the right product?
Explore all of our products under 萘啶酸
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Carc. 2
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Christopher M Parry
Transactions of the Royal Society of Tropical Medicine and Hygiene, 98(7), 413-422 (2004-05-13)
Multidrug-resistant (MDR) Salmonella Typhi (resistant to chloramphenicol, ampicillin, and trimethoprim-sulphamethoxazole) and isolates with reduced susceptibility to fluoroquinolones (indicated by resistance to nalidixic acid, NaR) have caused epidemics and become endemic in southern Viet Nam during the 1990s. Short courses of
George X Song-Zhao et al.
Mucosal immunology, 7(4), 763-774 (2013-11-28)
Polymorphisms in the intracellular pattern recognition receptor gene NLRP3 (NLR family, pyrin domain containing 3) have been associated with susceptibility to Crohn's disease, a type of inflammatory bowel disease. Following tissue damage or infection, NLRP3 triggers the formation of inflammasomes
Drug therapy reviews: nalidixic acid.
R Gleckman et al.
American journal of hospital pharmacy, 36(8), 1071-1076 (1979-08-01)